IL155443A0 - 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands - Google Patents

1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands

Info

Publication number
IL155443A0
IL155443A0 IL15544301A IL15544301A IL155443A0 IL 155443 A0 IL155443 A0 IL 155443A0 IL 15544301 A IL15544301 A IL 15544301A IL 15544301 A IL15544301 A IL 15544301A IL 155443 A0 IL155443 A0 IL 155443A0
Authority
IL
Israel
Prior art keywords
heterocyclylbenzazoles
hydroxytryptamine
alkylsulfonyl
ligands
aryl
Prior art date
Application number
IL15544301A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of IL155443A0 publication Critical patent/IL155443A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
IL15544301A 2000-11-02 2001-10-31 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands IL155443A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24511800P 2000-11-02 2000-11-02
PCT/US2001/045389 WO2002036562A2 (en) 2000-11-02 2001-10-31 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
IL155443A0 true IL155443A0 (en) 2003-11-23

Family

ID=22925357

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15544301A IL155443A0 (en) 2000-11-02 2001-10-31 1- aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
IL155443A IL155443A (en) 2000-11-02 2003-04-15 1-Aryl or 1-Alkylsulfonyl - the tricyclylbenzazoles, the process for their preparation and pharmaceutical preparations containing them for the treatment of disorders of the central nervous system affected by 6 HT-5 receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155443A IL155443A (en) 2000-11-02 2003-04-15 1-Aryl or 1-Alkylsulfonyl - the tricyclylbenzazoles, the process for their preparation and pharmaceutical preparations containing them for the treatment of disorders of the central nervous system affected by 6 HT-5 receptors

Country Status (19)

Country Link
US (3) US20020115670A1 (pl)
EP (2) EP1343756A2 (pl)
JP (1) JP4184077B2 (pl)
KR (1) KR100822655B1 (pl)
CN (1) CN1222511C (pl)
AR (1) AR034270A1 (pl)
AU (2) AU2005102A (pl)
BR (1) BR0115102B1 (pl)
CA (1) CA2426031C (pl)
EA (1) EA006205B1 (pl)
HU (1) HUP0303756A3 (pl)
IL (2) IL155443A0 (pl)
MX (1) MXPA03003800A (pl)
NO (1) NO326610B1 (pl)
NZ (1) NZ525592A (pl)
PL (1) PL213134B1 (pl)
TW (1) TWI282787B (pl)
WO (1) WO2002036562A2 (pl)
ZA (1) ZA200304188B (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003397A (es) 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
MXPA03011244A (es) * 2001-06-07 2004-02-27 Hoffmann La Roche Nuevos derivados de indol con afinidad por el receptor 5-ht6.
KR20040010709A (ko) 2001-06-15 2004-01-31 에프. 호프만-라 로슈 아게 5-ht6 수용체 친화력을 갖는 4-피페라지닐인돌 유도체
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物
ATE424825T1 (de) 2001-07-20 2009-03-15 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
GB0203811D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
NZ535239A (en) 2002-03-27 2008-03-28 Glaxo Group Ltd Quinoline derivatives and their use as 5-HT6 ligands
KR100657056B1 (ko) * 2002-06-05 2006-12-13 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료를 위한 5-ht6-수용체조절제로서 1-설폰일-4-아미노알콕시 인돌 유도체
BR0314363A (pt) 2002-09-17 2005-07-19 Hoffmann La Roche Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
TW200505904A (en) * 2003-02-14 2005-02-16 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
PL1558582T3 (pl) 2003-07-22 2006-05-31 Arena Pharm Inc Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
JP2007509898A (ja) 2003-11-03 2007-04-19 プロビオドルグ エージー 神経障害治療に有用な組合せ
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
PE20060574A1 (es) 2004-07-28 2006-06-24 Glaxo Group Ltd Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
BRPI0614343A2 (pt) * 2005-08-15 2011-03-22 Wyeth Corp derivados de 3-sulfonilindazol substituìdo como ligantes de 5-hidroxitriptamina-6
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
AU2007217040A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
US7713978B2 (en) 2006-03-31 2010-05-11 Nigel Paul King Compounds
JP2009532471A (ja) * 2006-04-05 2009-09-10 ワイス 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニル−3−ヘテロシクリルインダゾール誘導体
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
PL2114878T3 (pl) 2007-01-08 2011-05-31 Suven Life Sciences Ltd Związki 5-(heterocyklilo)alkilo-N-(arylosulfonylo)indolowe i ich zastosowanie jako ligandy 5-HT6
CA2672190C (en) * 2007-01-08 2013-02-05 Suven Life Sciences Limited 4-(heterocyclyl)alkyl-n-(arylsulfonyl) indole compounds and their use as 5-ht6 ligands
US20080200471A1 (en) * 2007-02-16 2008-08-21 Memory Pharmaceuticals Corporation 6' substituted compounds having 5-ht6 receptor affinity
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
WO2008136017A1 (en) 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
CA2695456A1 (en) * 2007-08-15 2009-02-19 Robert Dunn 3' substituted compounds having 5-ht6 receptor affinity
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
JP5536781B2 (ja) 2008-09-17 2014-07-02 スヴェン・ライフ・サイエンシズ・リミテッド アリールスルホンアミドアミン化合物および5−ht6リガンドとしてのそれらの使用
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
WO2010125135A1 (en) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
MX2012013197A (es) 2010-05-12 2013-04-03 Abbvie Inc Inhibidores de indazol de cinasa.
PL395469A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
HRP20170277T1 (hr) 2013-08-07 2017-05-19 Cadila Healthcare Limited N-cijanometilamidi kao inhibitori janus kinaze
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
CN103880750A (zh) * 2014-03-18 2014-06-25 上海皓元生物医药科技有限公司 一种替格列汀关键中间体的制备方法
WO2016004882A1 (en) * 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2965741C (en) 2014-11-03 2022-05-17 Iomet Pharma Ltd Pharmaceutical compound
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物
JP7007374B2 (ja) * 2016-09-23 2022-01-24 ノバルティス アーゲー 腱及び/又は靭帯損傷に使用するためのインダゾール化合物
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Fxr有限責任公司 含有雙環核心部分之新穎lxr調節劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3155008B2 (ja) * 1994-07-26 2001-04-09 ファイザー・インコーポレーテッド セロトニンアゴニストおよびアンタゴニストとしての4−インドール誘導体
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
SI0930302T1 (en) * 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
MXPA03003397A (es) * 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.

Also Published As

Publication number Publication date
PL362138A1 (pl) 2004-10-18
BR0115102B1 (pt) 2013-11-26
EP2298738B1 (en) 2012-09-19
CA2426031C (en) 2011-10-04
AU2002220051B2 (en) 2007-05-24
EA200300528A1 (ru) 2003-10-30
CN1484638A (zh) 2004-03-24
HUP0303756A3 (en) 2009-08-28
JP2004513111A (ja) 2004-04-30
US20040087595A1 (en) 2004-05-06
NO20031977D0 (no) 2003-04-30
EA006205B1 (ru) 2005-10-27
IL155443A (en) 2011-06-30
TWI282787B (en) 2007-06-21
HUP0303756A2 (hu) 2004-03-01
NZ525592A (en) 2004-07-30
JP4184077B2 (ja) 2008-11-19
US20040132741A1 (en) 2004-07-08
ZA200304188B (en) 2004-08-30
WO2002036562A3 (en) 2003-01-23
EP1343756A2 (en) 2003-09-17
EP2298738A1 (en) 2011-03-23
WO2002036562A2 (en) 2002-05-10
CA2426031A1 (en) 2002-05-10
PL213134B1 (pl) 2013-01-31
KR100822655B1 (ko) 2008-04-17
AR034270A1 (es) 2004-02-18
BR0115102A (pt) 2003-09-30
CN1222511C (zh) 2005-10-12
NO20031977L (no) 2003-06-30
MXPA03003800A (es) 2003-08-20
NO326610B1 (no) 2009-01-19
AU2005102A (en) 2002-05-15
KR20030040566A (ko) 2003-05-22
US20020115670A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
AU2005102A (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
IL157059A0 (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
IL156517A0 (en) Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
IL158445A0 (en) Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
PL370890A1 (pl) Pochodne azaindoliloalkiloaminy jako ligandy receptora 5-hydroksytryptaminy-6
ZA200500435B (en) 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands
IL156518A0 (en) Heteocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands
GB0102398D0 (en) Organometallic monoacylarylphosphines
AU7306201A (en) Substituted-triazolopyrimidines as anticancer agents
EP1300908A4 (en) FILTERED
IL162243A0 (en) Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
ZA200506416B (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
DE50105628D1 (en) Filter
IL158448A0 (en) Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
GB0012054D0 (en) Ligands
GB0115841D0 (en) Ligand
HK1055969A (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
HK1057208A (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
GB0028293D0 (en) Releasable ligand
GB0018143D0 (en) Complexes
GB0007785D0 (en) Complexes
GB0003439D0 (en) Immuno-active polysaccharide compounds
GB0029607D0 (en) Filters
GB0029606D0 (en) Filters
HK1056561A (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands